Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jingbin Zhang

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
European Urology Oncology|February 1, 2024
External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 TrialAshley E Ross, Jingbin Zhang, Huei-Chung Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2017
Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate CancerDaniel E Spratt, Jingbin Zhang, María Santiago-Jiménez, et al.
Nature Medicine|January 6, 2025
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trialJuanita Lopez, Thomas Powles, Fadi Braiteh, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
European Urology Oncology|February 1, 2024
External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 TrialAshley E Ross, Jingbin Zhang, Huei-Chung Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2017
Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate CancerDaniel E Spratt, Jingbin Zhang, María Santiago-Jiménez, et al.
Nature Medicine|January 6, 2025
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trialJuanita Lopez, Thomas Powles, Fadi Braiteh, et al.
Pageof 7